Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models

Pharmacological Reports

Volumn 64, Issue 1, 2012, Pages 191-204

  Mahmood, Danish ^a   Khanam, Razia ^a   Pillai, Krishna Kolappa ^a   Akhtar, Mohd ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Amphetamine; Learning and memory; MK 801; Schizophrenia

Indexed keywords

ACETYLCHOLINESTERASE; AMPHETAMINE; APOMORPHINE; CIPROXIFAN; CLOBENPROPIT; DIZOCILPINE; HALOPERIDOL; HISTAMINE H3 RECEPTOR; SCOPOLAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CLIMBING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FEMALE; HYPERACTIVITY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; OPEN FIELD TEST; RAT; SCHIZOPHRENIA;

EID: 84862188424     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(12)70746-6     Document Type: Article

References (63)

1. Abe H, Honma S, Ohtsu H, Honma K: Circadian rhythms in behavior and clock gene expressions in the brain of mice lacking histidine decarboxylase. Brain Res Mol Brain Res, 2004, 124, 178-187. (Pubitemid 38591570)
2. 3-receptor antagonist in mice. Fundam Clin Pharmacol, 2006, 20, 373-378.
3. 3 receptor in rat brain. Br J Pharmacol, 114, 1523-1524.
4. 3 receptors in the brain of 6-hydroxydopamine-lesioned rats: Eur J Neurosci, 2000, 12, 3823-3832.
5. Arrang JM: Histamine and schizophrenia. Int Rev Neurobiol, 2007, 78, 247-286.
6. Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC: Highly potent and selective ligands for histamine H3-receptors. Nature, 1987, 327, 117-123. (Pubitemid 17062756)
7. 3) of histamine receptor. Nature, 1983, 302, 832-837.
8. Bardgett ME, Points M, Ramsey-Faulkner C, Topmiller J, Roflow J, McDaniel T, Lamontagne T, Griffith MS: The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss. Neuropsychopharmacology, 2008, 33, 1980-1991. (Pubitemid 351832596)
9. 3 receptor antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration. Psychopharmacology, 2009, 205, 589-597.
10. 3 antagonist thioperamide dose-dependently enhances memory consolidation and reverses amnesia induced by dizocilpine or scopolamine in a one-trial inhibitory avoidance task in mice. Behav Brain Res, 2004, 154, 211-219.
11. Bhattacharya SK: Central histamine receptors in learning and memory in rats. Eur J Pharmacol, 1990, 183, 925-931.
12. 3 receptor antagonists, thioperamide and ciproxifan. Behav Brain Res, 2004, 153, 69-76.
13. -/-) and mast cell deficient W/Wv mice. Brain Res, 2003, 968, 162-166.
14. Chen Z, Zhao Q, Sugimoto Y, Fujii Y, Kamei C: Effects of histamine on MK-801-induced memory deficits in radial maze performance in rats. Brain Res, 1999, 839, 186-189. (Pubitemid 29389806)
15. 4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol, 2009, 157, 55-63.
16. Cool AR: Mesolimbic dopamine and its control of locomotor activity in rats: differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens. Psychopharmacology, 1986, 88, 451-459.
17. Costal B, Naylor RJ, Nohria V: Climbing behavior by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol, 1978, 50, 39-50. (Pubitemid 9202912)
18. Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, Conway PC, Dunn RW: Effects of atypical antipsychotics agents on social behavior in rodents. Pharmacol Biochem Behav, 1993, 45, 9-17.
19. Corbett R. Sorensen SM. Mondadori C: Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology, 1999, 21, S211-S218.
20. 4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci, 2005, 26, 462-469.
21. Dere E, De Souza MA, Spieler RE, Lin JS, Ohtsu H, Haas HL, Huston JP: Changes in motoric, exploratory and emotional behaviors and neuronal acetylcholine content and 5-HT turnover in histidine decarboxylase-KO mice. Eur J Neuroscience, 2004, 20, 1051-1058. (Pubitemid 39141311)
22. Dere E, De Souza MA, Topic B, Spieler RE, Haas HL, Huston JP: Histidine decarboxylase knockout mice show deficient non-reinforced episodic object memory, improved negatively reinforced water maze performance, and increased neo and ventrostriatal dopamine turnover. Learn Mem, 2003, 10, 510-519. (Pubitemid 37499779)
23. Ellenbroek BA: Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic of drugs. Pharmacol Ther, 1993, 57, 1-78.
24. Ellman GL, Courtney KD, Andres VJ, Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 1961, 7, 88-95.
25. Faucard R, Armand V, Héron A, Cochois V, Schwartz JC, Arrang JM: N-methyl-D aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J Neurochem, 2006, 98, 1487-1496. (Pubitemid 44200440)
26. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2- methylpyrrolidinyl] ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther, 2005, 313, 176-190. (Pubitemid 40411341)
27. Fulop AK, Foldes A, Buzas E, Hegyi K, Miklos IH, Romics L, Kleiber M et al.: Hyperlepinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. Endocrinology, 2003, 144, 4306-4314. (Pubitemid 37204829)
28. Haas HL, Sergeeva OA, Selbach O: Histamine in nervous system. Physiol Rev, 2008, 88, 1184-1241.
29. Hall DA, Stain JJ, Merquez HA, Gulley JM: Acomparison of amphetamine and methamphetamine induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology, 2008, 195, 469-478. (Pubitemid 350160487)
30. Hlinak Z, Krejci I: N-methyl-D-aspartate prevented memory deficits induced by MK-801 in mice. Physiol Res, 2003, 52, 809-812. (Pubitemid 38090112)
31. Hlinak Z, Krejci I: Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice. Behav Brain Res, 2000, 117, 147-151.
32. 3-antagonist clobenpropit on spatial memory deficits induced byMK-801 as evaluated by radial maze in Sprague-Dawley rats. Behav Brain Res, 2004, 151, 287-293.
33. Ichikawa J, Dai J, O'Laughlin IA, Fower WL, Meltzer HY: Atypical, but not typical antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens. Neuropsychopharmacology, 2002, 26, 325-339. (Pubitemid 34159210)
34. Itoh Y, Nishibori M, Oishi R, Saeki K: Neuronal histamine inhibits methamphetamine-induced locomotor hyperactivity in mice. Neurosci Lett, 1984, 48, 305-309. (Pubitemid 14054440)
35. Itoh Y, Onodera K, Sakurai E, Sato M, Watanabe T: Effects of dopamine antagonists on neuronal histamine release in the striatum of rats subjected to acute and chronic treatments with methamphetamine. J Pharmacol Exp Ther, 1996, 279, 271-276. (Pubitemid 27166921)
36. Iwabuchi K, Kubota Y, Ito C, Watanabe T, Yanai K: Methamphetamine and brain histamine: A study using histamine-related gene knockout mice. Ann NY Acad Sci, 2004, 1025, 129-134. (Pubitemid 39643854)
37. Kathmann M, Schlicker E, Gothert M: Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. Psychopharmacology, 1994, 116, 464-468. (Pubitemid 24374248)
38. 3 receptor drugs. Nat Rev Drug Discov, 2005, 4, 107-120.
39. 3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol, 2007, 73, 1215-1224.
40. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H et al.: Neurochemical and behavioral effects of ciproxifan, a potent histamine H3 receptor antagonist. J Pharmacol Exp Ther, 1998, 287, 658-666. (Pubitemid 29133666)
41. Lowry OH, Roseburgh NJ, Farr AL, Randal RL: Protein measurement with the folin phenol reagent. J Biol Chem, 1951, 193, 205-15.
42. Marchese G, Casu G, Casti P, Spada GP, Pani L: Evaluation of amphetamine induced hyperlocomotion and catalepsy following long acting risperidone administration in rats. Eur J Pharmacol, 2009, 620, 36-41.
43. 3receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther, 2007, 321, 1032-1045.
44. 3 antagonists on step through passive avoidance response and histidine decarboxylase activity in senescence- accelerated mice. Pharmacol Biochem Behav, 1995, 50, 321-325.
45. 3 receptor antagonist, on scopolamine induced learning deficits using an elevated plus maze test in mice. Life Sci, 1995, 57, 2137-2144.
46. 3-receptor on learning and memory, and cholinergic and monoaminergic systems in mice. Life Sci, 1997, 61, 355-361.
47. 3 receptor antagonists inhibit gastric protection by (R)-α-methyl histamine in the rat. Br J Pharmacol, 2000, 129, 1597-1600.
48. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC: Atypical neuroleptics enhance histamine turnover in brain via 5 HT2A receptor blockade. J Pharmacol Exp Ther, 1999, 288, 590-596. (Pubitemid 29119669)
49. 3 receptor. J Pharmacol Exp Ther, 2002, 300, 621-628.
50. 3 receptor antagonists potentiate methamphetamine self administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology, 2004, 29, 705-717.
51. 3- receptor antagonist, on learning and memory in an elevated plus-maze test in mice. Naunyn-Schmiedebergs Arch Pharmacol, 1998, 357, 508-513.
52. 3-receptor improves memory retention and reverses the cognitive deficits induced by scopolamine in a two trial place recognition task. Behav Brain Res, 2001, 124, 235-242.
53. Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatax JL, Watanabe T, Lin JS: Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knockout mice: Evidence for the role of brain histamine in behavioral and sleep wake control. J Neurosci, 2002, 22, 7695-7711. (Pubitemid 35386369)
54. 3-receptor antagonist/ inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in rat. J Neurosci, 2002, 22, 7272-7280.
55. 3 receptors in rat brain areas. Neuroscience, 1993, 52, 169-189.
56. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, Kirch DG, Linnoila M, Wyatt RJ: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res, 1995, 14, 93-104.
57. Protais P, Costentin J, Schwartz JC: Climbing behaviour induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology, 1976, 50, 1-6.
58. Ryu JH, Yanai K, Sakurai E, Kim CY, Watanabe T: Ontogenetic development of histamine receptor subtypes in rat brain demonstrated by quantitative autoradiography. Develop Brain Res, 1995, 87, 101-110.
59. 3heteroreceptor. Fundam Clin Pharmacol, 1994, 8, 128-137.
60. 3receptor antagonists on neuroleptic induced catalepsy in mice. Neuropsychopharmacology, 1995, 34, 97-99.
61. Simón VM, Parra A, Miñarro J, Arenas MC, Vinader- Caerols C, Aguilar MA: Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol, 2000, 10, 159-164. (Pubitemid 30227615)
62. Varty GB, Higgins GA: Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol, 1995, 287, 201-205.
63. 3 receptor antagonists and antipsychotic drugs. Brain Res, 2005, 1045, 142-149.